INDP Indaptus Therapeutics, Inc.

Nasdaq indaptusrx.com


$ 3.37 $ -0.18 (-5.17 %)    

Wednesday, 29-Oct-2025 14:23:04 EDT
QQQ $ 635.10 $ -0.45 (-0.07 %)
DIA $ 478.23 $ -0.36 (-0.08 %)
SPY $ 688.01 $ -0.75 (-0.11 %)
TLT $ 91.41 $ -0.47 (-0.51 %)
GLD $ 366.44 $ -3.15 (-0.85 %)
$ 3.45
$ 3.58
$ 3.30 x 100
$ 3.47 x 191
$ 3.33 - $ 3.50
$ 2.22 - $ 47.60
54,085
na
3.82M
$ 1.47
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-13-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 03-13-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-12-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 03-13-2024 12-31-2023 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Gainers Enanta Pharma (NASDAQ: ENTA) stock rose 15.6% to $9.13 during Friday's after-market session. The market value of t...

Core News & Articles

Gainers Indaptus Therapeutics (NASDAQ: INDP) stock moved upwards by 108.1% to $6.83 during Friday's regular session. The m...

 indaptus-reports-partial-response-from-decoy20-monotherapy-in-urothelial-cancer-combo-with-pd-1-inhibitor-shows-favorable-safety

Decoy20 monotherapy induces Partial Response in patient with urothelial cancer and liver metastasesDecoy20 combination with PD-...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION